Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ICU Medical, Inc. (ICUI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
171.19+1.74 (+1.03%)
At close: 04:00PM EDT
171.19 0.00 (0.00%)
After hours: 04:13PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close169.45
Open169.54
Bid171.05 x 1300
Ask272.99 x 800
Day's Range169.35 - 171.65
52 Week Range158.60 - 282.00
Volume131,733
Avg. Volume196,075
Market Cap4.091B
Beta (5Y Monthly)0.55
PE Ratio (TTM)398.12
EPS (TTM)0.43
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est215.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
6% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ICUI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ICU Medical, Inc.
    Analyst Report: ICU Medical, Inc.ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. After ICU’s acquisition of Hospira Infusion Systems from Pfizer in 2017, it became one of the largest players in this concentrated industry, holding top-tier positions in its major reporting segments: infusion consumables (37% of 2020 revenue), IV solutions (31%), infusion systems (28%), and critical care (4%). The combined entity remains primarily U.S. focused, generating over 70% of its sales domestically.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
Advertisement
Advertisement